8-K: uniQure Secures Key FDA Alignment for Huntington's Gene Therapy AMT-130, Paving Way for Early 2026 BLA Submission

uniQure N.V. announced alignment with the U.S. Food and Drug Administration on critical statistical analysis and manufacturing plans for its investigational Huntington's disease gene therapy, AMT-130, targeting a Biologics License Application submission in the first quarter of 2026.

Summary

• uniQure N.V. has achieved alignment with the U.S. Food and Drug Administration (FDA) on several key components of the statistical analysis plan (SAP) and Chemistry, Manufacturing and Controls (CMC) information for its investigational gene therapy, AMT-130, for Huntington's disease.
• This alignment supports a planned Biologics License Application (BLA) submission for AMT-130 in the first quarter of 2026, pursuing an accelerated approval pathway.
• The FDA agreed that the composite Unified Huntington's Disease Rating Scale (cUHDRS) may serve as an acceptable registrational, intermediate clinical endpoint for accelerated approval.
• The primary efficacy analysis for the BLA will evaluate the 3-year change in cUHDRS in high-dose AMT-130 patients compared to a propensity score-adjusted external control arm, utilizing the ENROLL-HD dataset.
• The FDA also agreed that validation of the AMT-130 manufacturing process can leverage experience and prior knowledge from the etranacogene dezaparvovec-drlb (HEMGENIX) process, complemented by additional full-scale AMT-130 GMP batches and a single Process Performance Qualification (PPQ) batch.
• uniQure plans to submit an updated SAP to the FDA in Q2 2025, initiate the PPQ run and present topline Phase I/II data in Q3 2025, hold a pre-BLA meeting in Q4 2025, and submit the BLA with a priority review request in Q1 2026.

Sentiment

Score: 8

Explanation: The announcement indicates significant positive progress in the regulatory pathway for AMT-130, with clear FDA alignment on key aspects of the BLA submission, including statistical analysis and manufacturing. This de-risks the regulatory process considerably and sets a clear timeline for potential market entry for a disease with high unmet need. The accelerated approval pathway and existing designations (RMAT, Breakthrough) further enhance the positive outlook. While risks inherent to clinical development remain, the regulatory clarity is a strong positive.

Positives

• Achieved alignment with the FDA on critical statistical analysis plan (SAP) and Chemistry, Manufacturing and Controls (CMC) information for AMT-130, significantly de-risking the regulatory pathway.
• FDA continues to support the use of composite Unified Huntington's Disease Rating Scale (cUHDRS) as an acceptable registrational, intermediate clinical endpoint for accelerated approval.
• FDA agreed to the use of the large ENROLL-HD dataset (~33,000 patients) as an external control for the primary analysis, which offers a substantially larger sample size, lower attrition rates, and longer average patient follow-up compared to previously used studies.
• FDA agreed that AMT-130 manufacturing process validation can leverage prior knowledge from the HEMGENIX process, potentially streamlining the process and reducing development time.
• AMT-130 has received both Regenerative Medicine Advance Therapy (RMAT) and Breakthrough Therapy designations from the FDA, indicating significant potential and facilitating expedited review.
• The company is pursuing an accelerated approval pathway, which could lead to earlier market access for a disease with high unmet medical need.

Risks

• Interim data from Phase I/II trials of AMT-130 may not be predictive of later data readouts that will serve as a basis for further regulatory interactions.
• Clinical trial data may not support BLA submissions or accelerated approvals, or may not be satisfactory to the FDA and other regulators.
• New analyses of existing data and results may produce different conclusions than established as of the date hereof.
• Current and future interactions with regulatory authorities may affect the initiation, timing, and progress of clinical trials, BLA submission plans, and pathways to regulatory approval.
• Uncertainties exist regarding the FDA's and other regulatory authorities' interpretation of the data from the company's Phase I/II clinical trials of AMT-130 and acceptance of the company's clinical programs and the regulatory approval process.
• Later developments with the FDA and other regulators could be inconsistent with the feedback received to date, and regulatory authorities may not accept the company's approach as a basis for accelerated approval.
• Risks related to the company's use of propensity-weighted external controls in connection with its statistical analysis of clinical outcomes.
• Risks related to the company's use of nominal p values as a basis for its statistical analyses.
• Uncertainty whether the measurements that the company is evaluating continue to be viewed as robust and sensitive measurements of disease progression.
• RMAT designation or any accelerated pathway may not ultimately lead to regulatory approval.
• The company's ability to obtain, maintain, and protect its intellectual property.
• The company's ability to fund its operations and to raise additional capital as needed and on acceptable terms.

Future Outlook

uniQure anticipates submitting a Biologics License Application (BLA) for AMT-130 in the first quarter of 2026, seeking priority review designation and leveraging an accelerated approval pathway. The company expects to present three-year top-line Phase I/II data in the third quarter of 2025.

Management Comments

• "We are very pleased with our continued, productive engagement with the FDA and the progress we've made toward a planned BLA submission for AMT-130 in the first quarter of 2026." Walid Abi-Saab, M.D., chief medical officer of uniQure.
• "We are pursuing an accelerated approval pathway supported by multiple years of clinical data a rigorous and differentiated approach that reflects the urgent need in Huntington's disease and our commitment to delivering the first disease-modifying treatment for people affected by this devastating disease." Walid Abi-Saab, M.D.
• "We are grateful to the FDA for their continued engagement and look forward to sharing three-year top-line data in the third quarter of 2025." Walid Abi-Saab, M.D.

Industry Context

This announcement positions uniQure as a leader in gene therapy for neurodegenerative diseases, specifically Huntington's disease, where there are currently no approved disease-modifying treatments. The progress with FDA alignment for AMT-130, including the use of external control data and leveraging prior manufacturing experience from HEMGENIX (another gene therapy), highlights the evolving regulatory landscape and scientific advancements in the gene therapy space. The pursuit of an accelerated approval pathway underscores the high unmet medical need in Huntington's disease and the potential for gene therapies to address such conditions.

Comparison to Industry Standards

• The use of the ENROLL-HD dataset, with approximately 33,000 patients, for external control in clinical trials is a robust approach, offering a substantially larger sample size, lower attrition rates, and longer average patient follow-up compared to previously used natural history studies like TRACK-HD and PREDICT-HD. This aligns with industry efforts to enhance the statistical power and generalizability of clinical trial results, especially for rare diseases where large randomized controlled trials are challenging.
• Leveraging manufacturing process validation experience from etranacogene dezaparvovec-drlb (HEMGENIX), uniQure's previously approved gene therapy, demonstrates an efficient and potentially de-risked approach to CMC requirements, setting a precedent for internal knowledge transfer in gene therapy development.
• The receipt of both Regenerative Medicine Advance Therapy (RMAT) and Breakthrough Therapy designations for AMT-130 signifies that the FDA recognizes the potential for substantial improvement over existing therapies for a serious condition, a benchmark for promising investigational treatments in the biotech industry.

Stakeholder Impact

• Shareholders: Positive impact due to significant progress in the regulatory pathway for a key pipeline asset (AMT-130), potentially leading to future revenue streams and increased valuation if approved. Reduced regulatory uncertainty.
• Patients with Huntington's Disease: Highly positive potential impact as AMT-130 aims to be the first disease-modifying treatment for a devastating neurodegenerative disorder with no current approved therapies to delay onset or slow progression. The accelerated approval pathway could bring the therapy to patients sooner.
• Employees: Positive impact from clear progress on a flagship program, potentially boosting morale and job security.
• Regulatory Authorities (FDA): Continued collaboration and alignment demonstrate effective engagement between the company and the agency, facilitating the review process for novel therapies.

Next Steps

• Submit updated Statistical Analysis Plan (SAP) to the FDA in Q2 2025.
• Initiate Process Performance Qualification (PPQ) run in Q3 2025.
• Present topline Phase I/II data per the SAP in Q3 2025.
• Hold a pre-BLA meeting with the FDA in Q4 2025.
• Submit Biologics License Application (BLA) with a request for priority review designation in Q1 2026.
• Host an investor conference call and webcast on June 2, 2025, at 8:30 a.m. ET.

Key Dates

Recommendation

Keywords

uniQure, AMT-130, Huntington's Disease, Gene Therapy, FDA, Biologics License Application, BLA, Accelerated Approval, Statistical Analysis Plan, CMC, Manufacturing, Clinical Trials, Neurodegenerative, Rare Disease, RMAT, Breakthrough Therapy